Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Garber

Showing results (511-520 of 605) with videos related to

Pageof 61
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in <i>BRCA1/2</i> CarriersGiulia Ongaro, Caroline Salafia, Rania Sheikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)Nadine Tung, Banu Arun, Michele R Hacker, et al.
Journal of General Internal Medicine|June 26, 2021
Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR StudyLydia E Pace, Nadine Tung, Yeonsoo S Lee, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 21, 2026
The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in Women with Pathogenic BRCA1/2 VariantsGiulia Ongaro, Caroline Salafia, Rania Sheikh, et al.
The New England Journal of Medicine|January 18, 1996
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancerM G FitzGerald, D J MacDonald, M Krainer, et al.
The New England Journal of Medicine|June 7, 2011
Exemestane for breast-cancer prevention in postmenopausal womenPaul E Goss, James N Ingle, José E Alés-Martínez, et al.
Breast Cancer Research : BCR|November 18, 2010
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersNadine Tung, Alexander Miron, Stuart J Schnitt, et al.
Breast Cancer Research and Treatment|February 25, 2010
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek, Tara M Friebel, Judy E Garber, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 18, 2019
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinomaAmin H Nassar, Sarah Abou Alaiwi, Saud H AlDubayan, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Pageof 61

Showing results (511-520 of 605) with videos related to

Sort By:
Pageof 61
Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in <i>BRCA1/2</i> CarriersGiulia Ongaro, Caroline Salafia, Rania Sheikh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2020
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)Nadine Tung, Banu Arun, Michele R Hacker, et al.
Journal of General Internal Medicine|June 26, 2021
Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR StudyLydia E Pace, Nadine Tung, Yeonsoo S Lee, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 21, 2026
The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in Women with Pathogenic BRCA1/2 VariantsGiulia Ongaro, Caroline Salafia, Rania Sheikh, et al.
The New England Journal of Medicine|January 18, 1996
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancerM G FitzGerald, D J MacDonald, M Krainer, et al.
The New England Journal of Medicine|June 7, 2011
Exemestane for breast-cancer prevention in postmenopausal womenPaul E Goss, James N Ingle, José E Alés-Martínez, et al.
Breast Cancer Research : BCR|November 18, 2010
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancersNadine Tung, Alexander Miron, Stuart J Schnitt, et al.
Breast Cancer Research and Treatment|February 25, 2010
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriersSusan M Domchek, Tara M Friebel, Judy E Garber, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 18, 2019
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinomaAmin H Nassar, Sarah Abou Alaiwi, Saud H AlDubayan, et al.
Developmental Cell|May 26, 2022
A human breast atlas integrating single-cell proteomics and transcriptomicsG Kenneth Gray, Carman Man-Chung Li, Jennifer M Rosenbluth, et al.
Pageof 61